Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Complement Therapeutics Ltd.. (2/23/22). "Press Release: Complement Therapeutics Ltd Raises EUR 5 Million Seed Financing by BGV and Forbion and Appoints Dr Rafiq Hasan as CEO". London.

Organisations Organisation Complement Therapeutics Ltd.
  Group Complement Therapeutics (CTx) (Group)
  Organisation 2 BioGeneration Ventures B.V. (BGV)
Products Product CTx001 gene therapy (Complement Therapeutics)
  Product 2 venture capital
Index term Index term Complement Therapeutics–SEVERAL: investment, 202202 seed financing round €5m from BGV + Forbion
Persons Person Hasan, Rafiq (Complement Therapeutics 202202– CEO before Exact Therapeutics + Bayer + Novartis)
  Person 2 Ford, John (Enterprise Therapeutics 201610– CEO before Ario Pharma 201312 CEO)

> Next-generation Complement Therapeutics based on the role of Factor H-related proteins in complement-mediated diseases

> Company emerges out of stealth mode with plans to raise a Series A round in 2022 to fund further preclinical and early clinical development

> Dr. Rafiq Hasan appointed as CEO with Dr. John Ford as independent director

Complement Therapeutics Ltd (CTx), a preclinical stage University of Manchester spinout, announced today the completion of its EUR 5 million seed financing round from BioGeneration Ventures (BGV) who provided the initial seed-funding in early 2021 and Forbion, two leading European venture capital firms.

Built on the pioneering research carried out by its three founders at the University of Manchester, Prof Simon J. Clark, Prof Paul Bishop, and Dr Richard Unwin, the CTx team will focus on addressing unmet needs in complement mediated diseases such as geographic atrophy due to dry age-related macular degeneration, a major cause of vision loss and blindness globally. In particular, the founders have conducted highly innovative research into the pathophysiology of complement driven diseases, having recently published work on the role of factor H related (FHR) proteins in age related macular degeneration (AMD; see references). In addition to its pipeline of therapeutic candidates, CTx has developed a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

The company also announced the appointments of two highly experienced industry executives, Dr Rafiq Hasan as Chief Executive Officer and Dr. John Ford as an independent director.

Dr Hasan has pursued a highly successful career in the pharma industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as SVP and Global Head of Ophthalmology at Bayer, Dr Hasan grew the business of Eylea® from launch to over USD 2.5bn in 5 years, including its launch in 5 indications in 3 years.

Dr Rafiq Hasan, Chief Executive Officer, CTx commented: “I am very excited to be joining CTx to advance innovative therapeutic modalities for the treatment of complement driven diseases such as dry AMD. With the ongoing support from our investors BGV and Forbion, I look forward to establishing the company as a leader in the field.”

Dr John Ford is an experienced biotechnology entrepreneur having co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). “Having worked with BGV and Forbion for many years, I am confident that we can continue to contribute to the growth of the CTx team.”

Dr Geert-Jan Mulder, Managing Partner at Forbion and CTx Board member commented: “We are pleased to have the opportunity to continue our successful track-record in investing in innovative companies in ophthalmology. Dr Dmitrij Hristodorov, Partner at Forbion and CTx Board member added: “Rafiq and I have been successfully working together at Bayer and I am excited to continue this collaboration with him and his team advancing new science towards products for patients that make a difference. CTx has all the ingredients to become the next-generation complement company for diseases of the eye and beyond.”

Dr Max Klement, Principal at BGV commented: “BGV identified Complement Therapeutics as a promising opportunity in complement biology late 2020. Together with the founders and the team, we developed the plans for the lead indication in ophthalmology and other indications. With this additional financing and support of Forbion, our longstanding joint venture partner, CTx is well positioned to develop novel ground-breaking therapies for patients suffering from complement driven diseases.”


For more information please contact:

Complement Therapeutics Ltd
Dr Rafiq Hasan, CEO

Forbion and BGV
Laura Asbjornsen

Consilium Strategic Communication
Ashley Tapp, Sue Charles
Tel: +44 (0)20 3709 5700

Notes to Editor

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 1.8 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 70 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

For more information, please visit:

About BGV

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies.

BGV manages over EUR 225 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.

BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.

BGV is based in Naarden, The Netherlands. For more information, please visit:

About Complement Therapeutics Ltd

Complement Therapeutics (CTx) is an early stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases as well as developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform.

The Company is a spin out from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade and its quantification. The CPM platform employs a unique methodology to quantify over 30 complement cascade proteins.

Our lead investigational product (CTx001) is a gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.


Cipriani, V. et al. Beyond factor H: The impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. American Journal of Human Genetics (2021).

Lorés-Motta, L. et al. Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. American Journal of Human Genetics (2021).

Cipriani, V. et al. Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration. Nature Communications (2020).

Clark, S.J., et al. Bruch’s Membrane Compartmentalizes Complement Regulation in the Eye with Implications for Therapeutic Design in Age-Related Macular Degeneration. Frontiers in Immunology (2017).

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Complement Therapeutics (CTx) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top